Lyra Therapeutics, Inc. (LYRA) Financial Ratios
7 years of historical data (2018–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
2.47
↓-97% vs avg
5yr avg: 82.18
30Y Low58.0·High145.9
ROE
↓
-185.0%
↑-89% vs avg
5yr avg: -97.8%
30Y Low-223%·High-54%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
LYRA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Lyra Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $781126 | $672M | $13.0B | $4.7B | $2.8B | $4.9B | — | — |
| Enterprise Value | $-5415874 | $666M | $13.1B | $4.7B | $2.8B | $4.8B | — | — |
| P/E Ratio → | -0.31 | — | — | — | — | — | — | — |
| P/S Ratio | 0.51 | 438.05 | 8375.26 | 3482.76 | 9933.23 | — | — | — |
| P/B Ratio | 2.47 | 57.96 | 145.93 | 58.78 | 82.50 | 65.73 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
LYRA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 434.01 | 8378.16 | 3461.94 | 9777.81 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
LYRA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Lyra Therapeutics, Inc. earns an operating margin of -6280.8%. Operating margins have compressed from -4131.0% to -6280.8% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -185.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | -10318.9% | — | — | 100.0% |
| Operating Margin | -6280.8% | -6280.8% | -4308.1% | -4131.0% | -15303.5% | — | — | -583.5% |
| Net Profit Margin | -6090.9% | -6090.9% | -4023.1% | -4055.6% | -15267.7% | — | — | -484.6% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| ROE | -185.0% | -185.0% | -73.7% | -96.1% | -80.0% | -54.1% | -222.5% | — |
| ROA | -89.4% | -89.4% | -49.6% | -67.1% | -64.1% | -46.2% | -80.9% | -23.8% |
| ROIC | -145.5% | -145.5% | -68.8% | -199.2% | — | -1046.3% | — | — |
| ROCE | -109.0% | -109.0% | -61.4% | -85.2% | -77.5% | -51.8% | -99.7% | -31.0% |
LYRA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $41M exceeds total debt of $34M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.97 | 2.97 | 0.30 | 0.05 | 0.04 | 0.03 | 0.45 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.53 | 0.05 | -0.35 | -1.29 | -0.97 | -0.88 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — |
Net cash position: cash ($41M) exceeds total debt ($34M)
LYRA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Lyra Therapeutics, Inc.'s current ratio of 3.41x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 6.97x to 3.41x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.41 | 3.41 | 5.35 | 6.97 | 2.63 | 15.54 | 1.94 | 12.72 |
| Quick Ratio | 3.41 | 3.41 | 5.35 | 6.97 | 2.63 | 15.54 | 1.94 | 12.72 |
| Cash Ratio | 3.21 | 3.21 | 5.24 | 6.77 | 2.51 | 15.27 | 1.88 | 12.19 |
| Asset Turnover | — | 0.02 | 0.01 | 0.01 | 0.01 | — | — | 0.05 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | 49.00 |
LYRA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Lyra Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $65M | $50M | $30M | $13M | $9M | $8M | $6M |
Peer Comparison
Compare LYRA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 LYRAYou | $781126 | -0.3 | — | — | 100.0% | -6280.8% | -185.0% | -145.5% | — |
 XNCR | $903M | -9.9 | — | — | 91.6% | -141.4% | -14.0% | -16.3% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 SINT | $9M | -0.4 | — | — | 45.3% | -1053.1% | -500.7% | -253.2% | — |
 ARWR | $11B | -6389.3 | 90.4 | 69.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 MCRB | $74M | 12.1 | — | 86.0 | -423.8% | -11910.1% | 19.6% | -90.3% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 AGIO | $2B | -3.9 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 ACRS | $586M | -9.2 | — | — | 73.3% | -975.9% | -50.2% | -53.5% | — |
 MRK | $277B | 15.4 | 10.7 | 22.4 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 AZN | $283B | 27.9 | 15.8 | 24.1 | 81.9% | 23.4% | 22.9% | 14.9% | 1.5 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See LYRA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LYRA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LYRA vs XNCR
Side-by-side business, growth, and profitability comparison vs Xencor, Inc..
Start ComparisonLYRA — Frequently Asked Questions
Quick answers to the most common questions about buying LYRA stock.
What is Lyra Therapeutics, Inc.'s P/E ratio?
Lyra Therapeutics, Inc.'s current P/E ratio is -0.3x. This places it at the 50th percentile of its historical range.
What is Lyra Therapeutics, Inc.'s ROE?
Lyra Therapeutics, Inc.'s return on equity (ROE) is -185.0%. The historical average is -118.6%.
Is LYRA stock overvalued?
Based on historical data, Lyra Therapeutics, Inc. is trading at a P/E of -0.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Lyra Therapeutics, Inc.'s profit margins?
Lyra Therapeutics, Inc. has 100.0% gross margin and -6280.8% operating margin.